Inhibitory effect of a TGFβ receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells

[1]  D. Gilmour,et al.  EMT 2.0: shaping epithelia through collective migration. , 2009, Current opinion in genetics & development.

[2]  Ronald R. Bean,et al.  Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. , 2009, Recent patents on anti-cancer drug discovery.

[3]  M. Kano,et al.  Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β Signaling , 2009, Journal of the National Cancer Institute.

[4]  S. Tsujitani,et al.  Recent results of therapy for scirrhous gastric cancer , 2009, Surgery Today.

[5]  Takeshi Imamura,et al.  Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-β* , 2009, Journal of Biological Chemistry.

[6]  M. Yashiro,et al.  DNA methyltransferase inhibitor 5‐aza‐CdR enhances the radiosensitivity of gastric cancer cells , 2009, Cancer science.

[7]  S. Nada,et al.  ZO-1- and ZO-2-dependent integration of myosin-2 to epithelial zonula adherens. , 2008, Molecular biology of the cell.

[8]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[9]  T. Sawada,et al.  A Novel Transforming Growth Factor β Receptor Kinase Inhibitor, A-77, Prevents the Peritoneal Dissemination of Scirrhous Gastric Carcinoma , 2008, Clinical Cancer Research.

[10]  M. Quintanilla,et al.  Functional blockade of Smad4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells. , 2008, Carcinogenesis.

[11]  Liang Xie,et al.  Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. , 2007, Cancer research.

[12]  H. Nakano,et al.  Cell contact-dependent regulation of epithelial-myofibroblast transition via the rho-rho kinase-phospho-myosin pathway. , 2007, Molecular biology of the cell.

[13]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[14]  K. Miyazono,et al.  Ki26894, a novel transforming growth factor‐β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line , 2007, Cancer science.

[15]  U. Certa,et al.  Polychaetoid/ZO-1 Is Required for Cell Specification and Rearrangement during Drosophila Tracheal Morphogenesis , 2006, Current Biology.

[16]  D. Ichikawa,et al.  Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. , 2004, American journal of surgery.

[17]  M. Yashiro,et al.  Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. , 2003, Cancer research.

[18]  Ray Keller,et al.  Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development , 2003, Mechanisms of Development.

[19]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[20]  E. Nomura,et al.  Expression of transforming growth factor β (TGF-β) may contribute, in part, to the variations in histogenesis and the prevalence of peritoneal dissemination in human gastric carcinoma , 2000, Gastric Cancer.

[21]  S. Tsujitani,et al.  An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. , 2000, Anticancer research.

[22]  K. Sugimachi,et al.  The progression of invasiveness regarding the role of transforming growth factor beta receptor type II in gastric cancer. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[23]  T. Sawada,et al.  Decrease in ICAM-1 expression on gastric cancer cells is correlated with lymph node metastasis , 1999, Gastric Cancer.

[24]  Y. Hishikawa,et al.  Overexpression of Transforming Growth Factor-β1 in Scirrhous Carcinoma of the Stomach Correlates with Decreased Survival , 1998, Oncology.

[25]  H. Kotani,et al.  Regulation of Cell–Cell Adhesion by Rac and Rho Small G Proteins in MDCK Cells , 1997, The Journal of cell biology.

[26]  T. Hasuma,et al.  Transforming Growth Factor‐β and Hepatocyte Growth Factor Produced by Gastric Fibroblasts Stimulate the Invasiveness of Scirrhous Gastric Cancer Cells , 1997, Japanese journal of cancer research : Gann.

[27]  Y. Chung,et al.  Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. , 1996, British Journal of Cancer.

[28]  M. Yashiro,et al.  Fibrosis in the peritoneum induced by Scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination , 1996, Cancer.

[29]  R. Takimoto,et al.  Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. , 1994, British Journal of Cancer.

[30]  H. Yokozaki,et al.  Expression of TGF‐β and procollagen type I and type III in human gastric carcinomas , 1989 .

[31]  Y Iwamoto,et al.  A rapid in vitro assay for quantitating the invasive potential of tumor cells. , 1987, Cancer research.

[32]  T. Motoyama,et al.  COMPARISON OF SEVEN CELL LINES DERIVED FROM HUMAN GASTRIC CARCINOMAS , 1986, Acta pathologica japonica.

[33]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[34]  P. Reitsma,et al.  Cardiovascular , Pulmonary and Renal Pathology Factor Xa Stimulates Proinflammatory and Profibrotic Responses in Fibroblasts via Protease-Activated Receptor-2 Activation , 2010 .

[35]  M. Kano,et al.  Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor (cid:1) Signaling , 2009 .

[36]  川尻 成美.  A novel transforming growth factor β receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma , 2008 .

[37]  Li Yang,et al.  Transforming Growth Factor B : Tumor Suppressor or Promoter ? Are Host Immune Cells the Answer ? , 2008 .

[38]  H. Shimada,et al.  Therapeutic strategy for scirrhous type gastric cancer. , 2005, Hepato-gastroenterology.

[39]  E. Nomura,et al.  Expression of transforming growth factor beta (TGF-beta) may contribute, in part, to the variations in histogenesis and the prevalence of peritoneal dissemination in human gastric carcinoma. , 2000, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.

[40]  T. Saito,et al.  Clinicopathologic prognostic features in patients with gastric cancer associated with esophageal or duodenal invasion. , 1999, Upsala journal of medical sciences.

[41]  K. Miyazono,et al.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins. , 1997, Nature.

[42]  K. Miyazono,et al.  Immunoelectron microscopic localization of transforming growth factor beta 1 and latent transforming growth factor beta 1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. , 1993, Cancer research.

[43]  K. Miyazono,et al.  Immunoelectron Microscopic Localization of Transforming Growth Factor β1 and Latent Transforming Growth Factor β1 Binding Protein in Human Gastrointestinal Carcinomas: Qualitative Difference between Cancer Cells and Stromal Cells , 1993 .